



July 1, 2024

**BSE Limited**

Department of Corporate Services,  
P. J. Towers, Dalal Street,  
Mumbai Samachar Marg,  
**MUMBAI - 400 001.**

✓ **National Stock Exchange of India Limited**

Exchange Plaza,  
Bandra Kurla Complex,  
Bandra (East),  
**MUMBAI - 400 051.**

*Dear Sir/Madam,*

**Sub: Disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations').**

Vide letter dated June 7, 2024, we had informed the Stock Exchanges as regards the Company, having entered into a Business Transfer Agreement with Lupin Life Sciences Limited, wholly owned subsidiary of the Company, to carve out, its trade generics business in India, as a going concern, on a slump sale basis.

We are pleased to inform you that today i.e. July 1, 2024, the Company has completed the said transfer. Thus, the transaction has been completed.

This may kindly be considered as disclosure pursuant to Regulation 30 of the Listing Regulations.

The above is for your information and dissemination.

Thanking you,

**For LUPIN LIMITED**

**R. V. SATAM**  
**COMPANY SECRETARY**  
**(ACS - 11973)**